Evidence map›Paper›PMID 37821747›Full record

ArticleEJNMMI radiopharmacy and chemistry2023

Au@

Nasrin Abbasi Gharibkandi, Kamil Wawrowicz, Agnieszka Majkowska-Pilip, Kinga Żelechowska-Matysiak, Mateusz Wierzbicki, Aleksander Bilewicz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Au@International journal of molecular sciences · 2024
    Article
  4. EJNMMI radiopharmacy and chemistry · 2024
    Article
  5. In Vitro Assessment ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nasrin Abbasi GharibkandiCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland.
Kamil WawrowiczCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland.
Agnieszka Majkowska-PilipCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland.
Kinga Żelechowska-MatysiakCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland.
Mateusz WierzbickiInstitute of Biology, Warsaw University of Life Sciences, Ciszewskiego 8 St., 02-786, Warsaw, Poland.
Aleksander BilewiczCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland. a.bilewicz@ichtj.waw.pl.ORCID http://orcid.org/0000-0003-2490-3303
Instytut Chemii i Techniki Jądrowej · PLJagiellonian University · PLWarsaw University of Life Sciences · PL

Funding

Narodowym Centrum Nauki 2022/45/B/ST5/01861
6 · The paper itself

Abstract

backgroundIn radionuclide therapy, to enhance therapeutic efficacy, an intriguing alternative is to ensure the simultaneous implementation of low- and high-LET radiation emitted from a one radionuclide. In the present study, we introduce the concept of utilizing

results

conclusionThe obtained results show that trastuzumab-functionalized

Indexed as

109Pd/109mAg in vivo generatorAuger electron therapyNanotechnologyRadioimmunotherapy

Identifiers

PMID37821747
PMCPMC10567614
OpenAlexW4387527110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.